Introduction
Multiple genetic factors are assumed to influence the development or progression of diabetic nephropathy based on previous reports [1] [2] [3] . Using a genome-wide, genebased single nucleotide polymorphism (SNP) approach, we found recently the gene encoding solute carrier family 12 (sodium/chloride transporters) member 3, SLC12A3, as a new candidate for conferring susceptibility to diabetic nephropathy in a Japanese population [4] . SLC12A3 is located on chromosome 16q13 and is expressed specifically in the kidneys, where it encodes a thiazide-sensitive Na-Cl cotransporter (NCCT) that mediates reabsorption of Na + and of Cl − in the distal convoluted tubule. Mutation of SLC12A3 is known to be responsible for Gitelman syndrome, an autosomal recessive renal tubular disorder characterised by hypokalaemic metabolic alkalosis, hypomagnesaemia, and low urinary calcium [5, 6] . We have identified several SNPs of this gene associated with nephropathy. In particular, +78G/A polymorphism in exon 23 (Arg913Gln) shows the strongest association among them. In the present study, to clarify whether polymor-phism of the +78G/A actually had an influence on the elevation of urinary albumin excretion, we examined the effect of this polymorphism in the patients with type 2 diabetes in a 10-year retrospective longitudinal study.
Subjects, materials and methods
Subjects and research design Two hundred and sixty-four unrelated Japanese patients with type 2 diabetes diagnosed by the criteria recommended by the American Diabetic Association (ADA) [7] , who showed normoalbuminuria or microalbuminuria at baseline (in 1993) and could be completely followed for 10 years (177 men and 87 women aged 53.2±0.7 years, mean±SEM), were recruited from the diabetic outpatients at Juntendo University Hospital or Saiseikai Central Hospital (Tokyo, Japan). Diabetic nephropathy is clinically characterised by persistent proteinuria, decline of GFR and hypertension. The elevated urinary excretion of albumin may not be a specific marker for nephropathy, but the earliest clinical evidence of nephropathy is the appearance of microalbuminuria. Thus, patients with microalbuminuria are referred to as having incipient nephropathy [8] . To specifically evaluate the associations of genotypes with albuminuria referred to nephropathy, we excluded patients with microscopic or macroscopic haematuria, abnormal urinary sediment, or a past history of glomerulonephritis or nephroureterolithiasis, renal pelvic dilation, or severe renal atrophy. All subjects gave written informed consent before enrolment in the study, which was approved by the Ethics Committees of Juntendo University or that of Saiseikai Central Hospital. Each year, the grade of albuminuria was determined from the average of at least two measurements of the urinary albumin:creatinine ratio (ACR) or AER, and was categorised as normoalbuminuria (ACR<30 mg/g Cre or AER<20 μg/min), microalbuminuria (30≦ACR<300 mg/g Cre or 20≦AER<200 μg/min), and overt proteinuria (ACR≧300 mg/g Cre or AER≧200 μg/min) by ADA recommendations [8] . BP, serum lipids, HbA 1 c and BMI values were calculated as the average over the 10-year period. The subjects were classified into two groups: group N showed persistent normoalbuminuria or microalbuminuria for 10 years, or regression from microalbuminuria to normoalbuminuria, while group P showed progression from normoalbuminuria to microalbuminuria or overt proteinuria over 10 years, or progression from microalbuminuria to overt proteinuria.
Genotyping of SNPs in the SLC12A3 gene Genomic DNA was extracted from peripheral blood cells using a DNA extraction kit (QIAamp DNA Blood Kit, Qiagen, Tokyo, Japan). On the basis of the GenBank information about the sequence containing the SLC12A3 gene (accession no. AC012181.6), we designed PCR primers to amplify target fragments. Genomic DNA was amplified using a forward primer (5′-TCCATGTGTCCTCCAGGATCATTTC-3′) and a reverse primer (5′-GATGCTAGATGGGGTCTGTATG TTGC-3′). The PCR products were purified and used for direct sequencing by the fluorescent dye-terminator cycle sequencing method (ABI) with the same primers as those for PCR reactions. 
Results
The changes of urinary albumin excretion in each group are summarised in Table 1 . Serum creatinine was elevated above 115 μmol/l in five patients from group P, but no patient progressed to endstage renal failure by the end of this study (2003) . Clinical characteristics at baseline and the +78G/A genotypes of the subjects in each group are shown in Table 2 . Seventy-eight patients (30%) were being treated with antihypertensive agents; the percentage of treated patients was higher in group P than in group N, but was not significantly different. There were 20 patients with the +78A(+) genotype in the study population, and all of them were heterozygotes. The frequency of the +78A allele was 3.8%, which was consistent with the previous report and the distribution of the genotype was within HardyWeinberg equilibrium. None of the subjects showed electrolyte abnormalities, familial inheritance, or other symptoms of Gitelman syndrome (data not shown). As shown in Table 2 , the percentage of patients with the +78A(+) genotype in group N was significantly higher than in group P, and the +78A allele frequency was also significantly higher in group N than in group P (10% vs 1%, p=0.021).
The baseline, final and 10-year mean values for various clinical characteristics are shown in Table 3 . The final and 10-year mean systolic BP and the 10-year mean diastolic BP were significantly higher in group P than in group N. All HbA 1 c values were significantly higher in group P than in group N, while the baseline and 10-year mean HDLcholesterol levels were significantly lower in group P than in group N. The other values did not differ between the two groups.
As shown in Table 4 , both logistic regression analysis and discriminant analysis using the forward selection method showed that the +78A(+) genotype and female sex were correlated negatively with the development of microalbuminuria and/or progression to macroalbuminuria, while the 10-year mean systolic BP, 10-year mean HbA 1 c, and percentage of smokers showed a positive correlation.
Discussion
As shown in Table 2 , the frequencies of retinopathy and prevalence of antihypertensive therapy were not different between the two groups, although the frequency of microalbuminuric patients at baseline in the group P was higher than that in the group N (31% vs 13%, p=0.002). However, these rates at baseline in microalbuminuric patients with retinopathy (46%) and with antihypertensive therapy (45%) were similar to those in the report for European type 2 diabetic patients [9] . Furthermore, the progression rate from microalbuminuria to overt proteinuria seen in the present study was 47% (22 out of 47 microalbuminuric patients), and this was consistent with the results from the previous prospective studies [10, 11] . Taken together, our subjects, especially microalbuminuric patients, are unlikely to be an unusual cohort, considering previous reports. The overall frequency of the +78A allele in our patients with type 2 diabetes was 3.8%, which did not differ from that in the Japanese general population (5.0%, unpublished data). Lemmink et al. detected the substitution of Gln for Arg at codon 913 in patients with Gitelman syndrome, but two patients who were homozygous for the +78 A allele showed no symptoms of Gitelman syndrome in our previous study [12] . Therefore, this substitution may not in itself be a cause of Gitelman syndrome.
Since little is known about the clinical association between BP and the +78G/A polymorphism [13] , we examined preliminarily whether +78 G/A polymorphism had an effect on 10-year mean BP in these patients. However, neither the 10-year mean systolic BP nor 10-year mean diastolic BP was significantly different between subjects with the +78A(−) and A(+) genotypes, and multiple regression analysis to investigate the association between +78G/A polymorphism and BP showed no significant correlation between them (data not shown). Therefore further research is needed to clarify mechanisms underlining the protective effect of the +78A genotype against the elevation of albumin excretion.
In conclusion, we found that the SLC12A3 +78G/A polymorphism in exon 23 (Arg913Gln) was associated with albumin excretion, and that the +78A allele may have a protective effect on the elevation of albuminuria in patients with type 2 diabetes.
